{"ticker": {"uuid": "62a5460f-1b30-4614-a90f-00d675677e6d", "symbol": "R2AR34", "name": "Ultragenyx Pharmaceutical Inc.", "exchange": "SAO", "country": "BR", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNeWw4am9xNmJjbnlwYlY3RXRfcml2cVA2V29ISmF0Vk1GVE5qVVpzWDl5YlJGNDRkY3ZrVkpTZ1AzTlk4WC05ekx1d2RrRmdWcWR0RE1Id0NNcHRfR0pKRDBqek04eVo2R1kzZFo5RG5aSVdYcWRGT2dsQkczY0pFcDJQc1hJSURianZTRFVfN1FsRm02bXFDT01jWnVQUmNkNk1aXzZqbmVUYjBFUjhXcFM1c0xQdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx director Suliman Shehnaaz sells $144,188 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQeWVBTDB4TUlHRmh3Q0t0LXdBaHN6dlpsQ3VOci1PN0Q2S0M3LTRESVBpWE1TZmw1SE1VSWRFeFNFM2s1TDI4cTlYa2VCbENFMGpXVS1MU3VXdEJVMHVHd2FFRE5VZWtpSThQZHN4bnZ4UlA1akxOcDh3ZDBrcGE1MVlmdjBHUXRzN0VkVEljclJBOXZZSk10NVM5c1FtVzVlTWp6OHRCeE1KMVlodWIwdUNiOXpUYnhjdWJqVE16X0c?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxORkhUMWRud3ppVmtKSk5TZWdPLWlOX3hKWFVJZmRtdkYyWFkzZTdmdkpOUEhEWWlFanpXNWUxWFJseFpwM2NsbHFnN1J4ZVBEUlp0bjdiMVZRTTg1b0tfZU9WbVljZm1pRW84Z0x3RlNoVUIyMmxPSUxhQlNoTENpNjFpTW5CY0VsWEtNSEZfbjRKZkZ6TERZSkNGRmwwRkVUYV80N1FtWFUyc05xaEdfaXJjOHVabVRUZVg5cmtHeFA2RExNQlMwM09GX1diSS1wcHNCSGRMU3dILUplWmh1NWQ1MXlqekU?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAJBVV95cUxQYUx3R3FHWFo1Njl0Z3lCWjF6MXc2VU1NWllwY0hyTUhDaEdoX0RMNzNBOHkxMTRqc0I1UmFWeTNVWHFOYmI5czVMS0NWOFZwa2FTcVY3bE9ubnhaSHEySThBa3lmQXNwN3c3WUtfd0F1MDFSSno0ZHJTLS1IYWdpdG1IaW1iMUNnN1dEVFdGVk4yMHBGYXY4ODNUNDU5YTdwaDZhSnEwaVMyNTVweWg2XzV6UGdDUDlpTnNDMVZfMWZrMnpfcTQtZEU3a211cVh4UDZfeVUyVXc0a0ZsS3VFMm1BY2xjdnJVdkptVXprMnNVMmQwazB1eGp2S2tlUnpRWkZxU2hOT3hFbnBpZ2lLcVpoS1dySm9qS3AwX3lLOVY0OWx1WFJnWEV2YWdTQzg0RHEwY2JEbGxlRUN2dE9OV1UteGJJQzVZ?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPLTYzWjhDelNPSVBDVDczTjY1Q2FPWFRjbHQ1TEt4aGpFVnBPVGk0UTZCdXBXR3ZPankwbkZzZ3BMb3dQSjJyZ1RBSFpUbnMyVHNfd0gxbHA0VU5mQlVmdE9Ub1B1M3lzazNHNmxUTjE0OVdjYUduQjB4NWJjczhMbjkxQ0ZIWGdnSzFmazRpM3k5Zjk4MW5CSkxqV3FvemxWZlZlTVJOU3RNQlJ0ZkFPRkw3cTFIdFozaDJMdUNqeTBuMVpwc1F4S2ZNeWVPY2hZamlTQ0NJMVNGay1qOWVRSXBR?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx (RARE) Stock: Gains Spotlight After Completing FDA BLA for First-in-Class Gene Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQMndKLWlSXzh1cTNyeTM2UVBXQmg4LW1ma0oxYlpGRWdqSFlBYk5iNlFLcnZEbWpMSHdSUVo2ZEpRLUtkc1ZGZEV1RVg5LXkxc1VvTjVLbjhjYmo3dHdIV19oa0hva2V4eHZySEtQeER0VExvS2xkM3phQ3dIejVfSi14Y0hTenUxaEtDSkNxR25uQXJtVExyZGNRWEp5bTlqTGZhMWhJLXo3aEZsVFlmY1NVZThFWVE?oc=5", "source_name": "parameter.io", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Pharmaceutical Stock Price Forecast. Should You Buy RARE?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE12YjRkNk5TMkt4dXZPMU1Bb3hMbXlZSUY0cHYzYTJsTXh5dWFDWV8xemNPaUVsTko0UGtmWDFENUhpQ3c0UGVaNA?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-02T21:55:40+00:00", "published_display": "02 Dec 2020 21:55", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Reports First Quarter 2019 Financial Results and Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQR2t4NWZuWGZEQVFrYl9FRl91WE9JU3R6WXppUHdpa0VicTBualJLT0xBcVhzQUw0Zi1VMHFoUTVsNi0yWGFkaG15QXgzTW40MjFvZDB1TXFrTUdFTEhBcm9HN1VraFlDSnJNR2FzQS02Z0piTGM0NkVZTkIyV1VMS2ROY2FrOW9DNzdmY25TZnhwbmpzVEVKbDJodW5fTTlrdDdOS2xfS19vWkZ6bGM3M3NRamZ5ZDdja0xGOEVpdkhSaGp5VFFYZ1FVVzFpOTg1b0pCbVVndDl5S2dEejVUOVB4Wl9CSDA?oc=5", "source_name": "GlobeNewswire", "published_at": "2019-05-06T07:00:00+00:00", "published_display": "06 May 2019 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNeWw4am9xNmJjbnlwYlY3RXRfcml2cVA2V29ISmF0Vk1GVE5qVVpzWDl5YlJGNDRkY3ZrVkpTZ1AzTlk4WC05ekx1d2RrRmdWcWR0RE1Id0NNcHRfR0pKRDBqek04eVo2R1kzZFo5RG5aSVdYcWRGT2dsQkczY0pFcDJQc1hJSURianZTRFVfN1FsRm02bXFDT01jWnVQUmNkNk1aXzZqbmVUYjBFUjhXcFM1c0xQdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx director Suliman Shehnaaz sells $144,188 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQeWVBTDB4TUlHRmh3Q0t0LXdBaHN6dlpsQ3VOci1PN0Q2S0M3LTRESVBpWE1TZmw1SE1VSWRFeFNFM2s1TDI4cTlYa2VCbENFMGpXVS1MU3VXdEJVMHVHd2FFRE5VZWtpSThQZHN4bnZ4UlA1akxOcDh3ZDBrcGE1MVlmdjBHUXRzN0VkVEljclJBOXZZSk10NVM5c1FtVzVlTWp6OHRCeE1KMVlodWIwdUNiOXpUYnhjdWJqVE16X0c?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxORkhUMWRud3ppVmtKSk5TZWdPLWlOX3hKWFVJZmRtdkYyWFkzZTdmdkpOUEhEWWlFanpXNWUxWFJseFpwM2NsbHFnN1J4ZVBEUlp0bjdiMVZRTTg1b0tfZU9WbVljZm1pRW84Z0x3RlNoVUIyMmxPSUxhQlNoTENpNjFpTW5CY0VsWEtNSEZfbjRKZkZ6TERZSkNGRmwwRkVUYV80N1FtWFUyc05xaEdfaXJjOHVabVRUZVg5cmtHeFA2RExNQlMwM09GX1diSS1wcHNCSGRMU3dILUplWmh1NWQ1MXlqekU?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAJBVV95cUxQYUx3R3FHWFo1Njl0Z3lCWjF6MXc2VU1NWllwY0hyTUhDaEdoX0RMNzNBOHkxMTRqc0I1UmFWeTNVWHFOYmI5czVMS0NWOFZwa2FTcVY3bE9ubnhaSHEySThBa3lmQXNwN3c3WUtfd0F1MDFSSno0ZHJTLS1IYWdpdG1IaW1iMUNnN1dEVFdGVk4yMHBGYXY4ODNUNDU5YTdwaDZhSnEwaVMyNTVweWg2XzV6UGdDUDlpTnNDMVZfMWZrMnpfcTQtZEU3a211cVh4UDZfeVUyVXc0a0ZsS3VFMm1BY2xjdnJVdkptVXprMnNVMmQwazB1eGp2S2tlUnpRWkZxU2hOT3hFbnBpZ2lLcVpoS1dySm9qS3AwX3lLOVY0OWx1WFJnWEV2YWdTQzg0RHEwY2JEbGxlRUN2dE9OV1UteGJJQzVZ?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPLTYzWjhDelNPSVBDVDczTjY1Q2FPWFRjbHQ1TEt4aGpFVnBPVGk0UTZCdXBXR3ZPankwbkZzZ3BMb3dQSjJyZ1RBSFpUbnMyVHNfd0gxbHA0VU5mQlVmdE9Ub1B1M3lzazNHNmxUTjE0OVdjYUduQjB4NWJjczhMbjkxQ0ZIWGdnSzFmazRpM3k5Zjk4MW5CSkxqV3FvemxWZlZlTVJOU3RNQlJ0ZkFPRkw3cTFIdFozaDJMdUNqeTBuMVpwc1F4S2ZNeWVPY2hZamlTQ0NJMVNGay1qOWVRSXBR?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx (RARE) Stock: Gains Spotlight After Completing FDA BLA for First-in-Class Gene Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQMndKLWlSXzh1cTNyeTM2UVBXQmg4LW1ma0oxYlpGRWdqSFlBYk5iNlFLcnZEbWpMSHdSUVo2ZEpRLUtkc1ZGZEV1RVg5LXkxc1VvTjVLbjhjYmo3dHdIV19oa0hva2V4eHZySEtQeER0VExvS2xkM3phQ3dIejVfSi14Y0hTenUxaEtDSkNxR25uQXJtVExyZGNRWEp5bTlqTGZhMWhJLXo3aEZsVFlmY1NVZThFWVE?oc=5", "source_name": "parameter.io", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Pharmaceutical Stock Price Forecast. Should You Buy RARE?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE12YjRkNk5TMkt4dXZPMU1Bb3hMbXlZSUY0cHYzYTJsTXh5dWFDWV8xemNPaUVsTko0UGtmWDFENUhpQ3c0UGVaNA?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-02T21:55:40+00:00", "published_display": "02 Dec 2020 21:55", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Reports First Quarter 2019 Financial Results and Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQR2t4NWZuWGZEQVFrYl9FRl91WE9JU3R6WXppUHdpa0VicTBualJLT0xBcVhzQUw0Zi1VMHFoUTVsNi0yWGFkaG15QXgzTW40MjFvZDB1TXFrTUdFTEhBcm9HN1VraFlDSnJNR2FzQS02Z0piTGM0NkVZTkIyV1VMS2ROY2FrOW9DNzdmY25TZnhwbmpzVEVKbDJodW5fTTlrdDdOS2xfS19vWkZ6bGM3M3NRamZ5ZDdja0xGOEVpdkhSaGp5VFFYZ1FVVzFpOTg1b0pCbVVndDl5S2dEejVUOVB4Wl9CSDA?oc=5", "source_name": "GlobeNewswire", "published_at": "2019-05-06T07:00:00+00:00", "published_display": "06 May 2019 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 59, "total_relevant": 8, "sentiment_summary": {"positive": 2, "negative": 2, "neutral": 4, "score": 48, "total": 8, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 70, "events": [{"event": "general", "label": "Market update", "weight": 2.0, "count": 3}, {"event": "earnings", "label": "Earnings", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 2, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 17.08, "latest_week": "2026-07-03", "one_week_move": 42.5, "four_week_move": null, "twelve_week_move": null, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.0, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": 28.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 0.0, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+42.5% over one week, - over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 57, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "GlobeNewswire", "count": 2}, {"label": "PR Newswire", "count": 2}, {"label": "Seeking Alpha", "count": 1}, {"label": "Investing.com", "count": 1}, {"label": "parameter.io", "count": 1}, {"label": "StockInvest.us", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 8}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 3}, {"label": "Earnings", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "70/100 classification confidence."}, {"label": "Company focus", "value": "8", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+42.5% over one week, - over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity"}], "updated_at": "2026-07-08T00:08:08.055119+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}